Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, reflects on the company’s three-year evolution as a clinical trials partner, highlighting its pharmacy-led model and ...

Why a fundamental reimagining of how clinical studies operate is still necessary to achieve a true paradigm shift—and shed ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Over the past decade, artificial intelligence (AI) and automation have reshaped clinical research. From identifying drug ...

In this video interview, Heather Horville, solutions consultant at Greenphire, emphasizes the growing need for clinical operations to embed patient-centric services—from consent through final visit—to ...